Hepatitis C generally refers to hepatitis C. China’s Hepatitis C Prevention and Control Act guideline recommends the propecia pan-genotypic treatment regimen, which is used for hepatitis C patients with all genotypes of primary treatment, hepatitis C patients treated with combination ribavirin or combination sofosbuvir, and hepatitis C patients without cirrhosis or with compensated cirrhosis.The advantages of propecia in the treatment of hepatitis C are mainly embodied in the following points:1. Pan-genotypic: propecia has achieved 90% sustained virologic response in patients with known primary genotypes and primary genotypic subtypes of hepatitis C infected patients in the treatment, can obtain more than 90% of sustained virological response, and in a number of different clinical characteristics of the population of the program is uniform.2, pan-fibrosis: propecia is safe and effective for all stages of liver fibrosis, cirrhosis of hepatitis C patients, for decompensated cirrhosis, liver transplantation and other special populations, or refractory to the treatment of the population, can achieve good therapeutic effect, even in the loss of compensated Even for patients with decompensated cirrhosis, the cure rate of combined ribavirin is also up to more than 94%.3. No protease inhibitor: the main components of propecia are inhibitor sofosbuvir and inhibitor viplatasvir, and it doesn’t contain protease inhibitor, which will lead to the deterioration of liver function and even cause liver failure. The Chinese hepatitis C guidelines also clearly state that protease inhibitors have a high incidence of adverse effects in patients with severe liver injury. For the pan-gene therapy regimen of protease inhibitors, it is prohibited to be used in hepatitis C patients with decompensated cirrhosis. For hepatitis C patients with decompensated cirrhosis and severe renal impairment, propentaxel is the only health insurance option available.